Variability of repeated serum prostate-specific antigen (PSA) measurements within less than 90 days in a well-defined patient population

Urology

Volumn 47, Issue 1, 1996, Pages 59-66

  Roehrborn, Claus G ^a   Pickens, G John ^a   Carmody III, Thomas ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; BLOOD LEVEL; CANCER SCREENING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT PLANNING;

EID: 0030049965     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)80383-5     Document Type: Article

References (10)

1. Costongs GM, Janson PC, Bas BM, Hermans J, van Wersch JW, and Brombacher PJ: Short-term and long-term intra-individual variations and critical differences of clinical chemistry laboratory parameters. J Clin Chem Clin Biochem 23: 7-16, 1985.
2. Oesterling JE: Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145: 907-923, 1991.
3. Sershon PD, Barry MJ, and Oesterling JE: Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer. Eur Urol 25: 281-287, 1994.
4. Monda JM, Barry MJ, and Oesterling JE: Prostate specific antigen cannot distinguish stage T1a (A1) prostate cancer from benign prostatic hyperplasia. J Urol 151: 1291-1295, 1994.
5. Chybowski FM, Bergstralh EJ, and Oesterling JE: The effect of digital rectal examination on the serum prostate specific antigen concentration: results of a randomized study. J Urol 148: 83-86, 1992.
6. Crawford ED, Schutz MJ, Clejan S, Drago J, Resnick MI, Chodak GW, Gomella LG, Austenfeld M, Stone NN, Miles BJ, et al: The effect of digital rectal examination on prostate-specific antigen levels. JAMA 267: 2227-2228, 1992.
7. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, and Lieber MM: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 270: 860-864, 1993.
8. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, Fozard JL, and Walsh PC: Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220, 1992.
9. Riehmann M, Rhodes PR, Cook TD, Grose GS, and Bruskewitz RC: Analysis of variation in prostate-specific antigen values. Urology 42: 390-397, 1993.
10. Barry MJ, Girman CJ, O'Leary MP, Walker-Corkery ES, Binkowitz BS, Cockett AT, and Guess HA: Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group. J Urol 153: 99-103, 1995.